Colistin exposure as a risk factor for infections caused by inherently colistin resistant Enterobacteriaceae—a case–control study

Drozdinsky, Genady; Ben‐Zvi, Haim; Kushnir, Shiri; Leibovici, Leonard; Yahav, Dafna

doi:10.1016/j.cmi.2017.11.022

Cited by 7 publications

(3 citation statements)

References 10 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, to nearby countries, colistin resistant K. pneumoniae strains in Israel are genetically diverse with different sequence types including ST16, ST76, ST258, and ST512 (Lalaoui et al, 2019). Indeed, this country lacks quantitative investigation of the dosages and/or duration of colistin administration that significantly increase the risk of development of colistin resistance in a strain or a patient (Drozdinsky et al, 2018).…”

Section: Distribution Of Multi-drug Resistant Organisms In Humansmentioning

confidence: 99%

Understanding the Epidemiology of Multi-Drug Resistant Gram-Negative Bacilli in the Middle East Using a One Health Approach

et al. 2019

View full text Add to dashboard Cite

In the last decade, extended-spectrum cephalosporin and carbapenem resistant Gram-negative bacilli (GNB) have been extensively reported in the literature as being disseminated in humans but also in animals and the environment. These resistant organisms often cause treatment challenges due to their wide spectrum of antibiotic resistance. With the emergence of colistin resistance in animals and its subsequent detection in humans, the situation has worsened. Several studies reported the transmission of resistant organisms from animals to humans. Studies from the middle east highlight the spread of resistant organisms in hospitals and to a lesser extent in livestock and the environment. In view of the recent socio-economical conflicts that these countries are facing in addition to the constant population mobilization; we attempt in this review to highlight the gaps of the prevalence of resistance, antibiotic consumption reports, infection control measures and other risk factors contributing in particular to the spread of resistance in these countries. In hospitals, carbapenemases producers appear to be dominant. In contrast, extended spectrum beta lactamases (ESBL) and colistin resistance are becoming a serious problem in animals. This is mainly due to the continuous use of colistin in veterinary medicine even though it is now abandoned in the human sphere. In the environment, despite the small number of reports, ESBL and carbapenemases producers were both detected. This highlights the importance of the latter as a bridge between humans and animals in the transmission chain. In this review, we note that in the majority of the Middle Eastern area, little is known about the level of antibiotic consumption especially in the community and animal farms. Furthermore, some countries are currently facing issues with immigrants, poverty and poor living conditions which has been imposed by the civil war crisis. This all greatly facilitates the dissemination of resistance in all environments. In the one health concept, this work re-emphasizes the need to have global intervention measures to avoid dissemination of antibiotic resistance in humans, animals and the environment in Middle Eastern countries.

show abstract

Section: Distribution Of Multi-drug Resistant Organisms In Humansmentioning

confidence: 99%

Understanding the Epidemiology of Multi-Drug Resistant Gram-Negative Bacilli in the Middle East Using a One Health Approach

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A multicenter study collected colistin-resistant Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae from the bloodstreams of patients and found that previous treatment with colistin, a preceding colonization of resistant K. pneumoniae , and a Charlson score of ≥3 were correlated with CoRB infection [60, 61]. Previous treatment with colistin also has been associated with CoR Enterobacteriaceae infection in a matched case control study by Drozdinsky et al [62]. A possible relationship exists between neurological disorders and CoR K. pneumoniae infections [63], though this phenomenon was described only in few researches and needs further verification.…”

Section: Risk Factors and Prognosis For Corb Infectionmentioning

confidence: 99%

Emergent Polymyxin Resistance: End of an Era?

Cao

et al. 2019

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Until recently, the polymyxin antibiotics were used sparingly due to dose limiting toxicities. However, the lack of therapeutic alternatives for infections caused by highly resistant Gram-negative bacteria has led to the increased use of the polymyxins. Unfortunately, the world has witnessed increased rates of polymyxin resistance in the last decade, which is likely in part due to its irrational use in human and veterinary medicine. The spread of polymyxin resistance has been aided by the dissemination of the transferable polymyxin-resistance gene, mcr, in humans and the environment. The mortality of colistin-resistant bacteria (CoRB) infections varies in different reports. However, poor clinical outcome was associated with prior colistin treatment, illness severity, complications, and multidrug resistance. Detection of polymyxin resistance in the clinic is possible through multiple robust and practical tests, including broth microdilution susceptibility testing, chromogenic agar testing, and molecular biology assays. There are multiple risk factors that increase a person’s risk for infection with a polymyxin-resistant bacteria, including age, prior colistin treatment, hospitalization, and ventilator support. For patients that are determined to be infected by polymyxin-resistant bacteria, various antibiotic treatment options currently exist. The rising trend of polymyxin resistance threatens patient care and warrants effective control.

show abstract

“…Colistin is a polymyxin antibiotic that is considered as the final line of treatment for multidrugresistant Gram-negative bacteria (Li et al,2006) and exposure to colistin is associated with an increased risk of isolating colistin-resistant Enterobacteriaceae (Drozdinsky et al, 2017). Also the use of azoles-based antifungals (the most frequently used classes of antifungal therapy) may induce resistance in fungi (Fuentefria et al, 2017).…”

Section: Treatment With Antimicrobialsmentioning

confidence: 99%

Risk of survival, establishment and spread of Batrachochytrium salamandrivorans (Bsal) in the EU

Miranda²,

Bicout

et al. 2018

EFS2

View full text Add to dashboard Cite

Batrachochytrium salamandrivorans (Bsal) is an emerging fungal pathogen of salamanders. Despite limited surveillance, Bsal was detected in kept salamanders populations in Belgium, Germany, Spain, the Netherlands and the United Kingdom, and in wild populations in some regions of Belgium, Germany and the Netherlands. According to niche modelling, at least part of the distribution range of every salamander species in Europe overlaps with the climate conditions predicted to be suitable for Bsal. Passive surveillance is considered the most suitable approach for detection of Bsal emergence in wild populations. Demonstration of Bsal absence is considered feasible only in closed populations of kept susceptible species. In the wild, Bsal can spread by both active (e.g. salamanders, anurans) and passive (e.g. birds, water) carriers; it is most likely maintained/spread in infected areas by contacts of salamanders or by interactions with anurans, whereas human activities most likely cause Bsal entry into new areas and populations. In kept amphibians, Bsal contamination via live silent carriers (wild birds and anurans) is considered extremely unlikely. The risk-mitigation measures that were considered the most feasible and effective: (i) for ensuring safer international or intra-EU trade of live salamanders, are: ban or restrictions on salamander imports, hygiene procedures and good practice manuals; (ii) for protecting kept salamanders from Bsal, are: identification and treatment of positive collections; (iii) for on-site protection of wild salamanders, are: preventing translocation of wild amphibians and release/return to the wild of kept/temporarily housed wild salamanders, and setting up contact points/emergency teams for passive surveillance. Combining several risk-mitigation measures improve the overall effectiveness. It is recommended to: introduce a harmonised protocol for Bsal detection throughout the EU; improve data acquisition on salamander abundance and distribution; enhance passive surveillance activities; increase public and professionals' awareness; condition any movement of captive salamanders on Bsal known health status.

show abstract

Colistin exposure as a risk factor for infections caused by inherently colistin resistant Enterobacteriaceae—a case–control study

Cited by 7 publications

References 10 publications

Understanding the Epidemiology of Multi-Drug Resistant Gram-Negative Bacilli in the Middle East Using a One Health Approach

Understanding the Epidemiology of Multi-Drug Resistant Gram-Negative Bacilli in the Middle East Using a One Health Approach

Emergent Polymyxin Resistance: End of an Era?

Risk of survival, establishment and spread of Batrachochytrium salamandrivorans (Bsal) in the EU

Contact Info

Product

Resources

About